A phase IIa study of prolonged use of cannabidiol in the prevention of Graft versus Host Disease

Trial Profile

A phase IIa study of prolonged use of cannabidiol in the prevention of Graft versus Host Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2018

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Sponsors TALENT Biotech
  • Most Recent Events

    • 20 Sep 2018 According to a Kalytera Therapeutics media release, Dr. Moshe Yeshurun, Kalytera's Chief Medical Officer, was the Principal Investigator for the study. The study was conducted conducted at the Institute of Hematology, Davidoff Center, Rabin Medical Center, Petah Tikva, Israel.
    • 16 Feb 2017 Results published in a Kalytera Therapeutics media release.
    • 03 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top